Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the therapeutic efficacy and the safety of the new compression system URGO BD001 in the management of venous or mixed predominantly venous leg ulcers. The therapeutic efficacy will be the reduction in wound surface area during a six weeks study treatment period.
The compression bandage URGO BD001 is indicated for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous oedema and lymphedema justifying strong compression.
The pressure applied with the compression system URGO BD001 help to improve venous return and to reduce venous oedema. The expected clinical benefits from the compression system URGO BD001 in patient with a VLU are to increase healing rate and time to healing, and to improve patient quality of life.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| URGOBD001 | Experimental | Compression bandage |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Compression bandage | Device | Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous |
|
| Measure | Description | Time Frame |
|---|---|---|
| Relative reduction in wound surface area (percent) | Evolution between D0 and the 6 weeks treatment period with the URGO BD001 compression system: Relative reduction in wound surface area (%) = [(SW6 - SD0)/SD0] × 100 SD0: Wound surface area at D0 SW6: Wound surface area at Week 6 | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Complete ulcer closure: | The percent (%) of patients with complete ulcer closure (100% re-epithelialization) after 6 weeks or at the latest treatment period | 6 weeks or last assessment |
| Venous oedema |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Batot Géraldine, PhD | Contact | +33 3 80 44 28 46 | g.batot@fr.urgo.com | |
| Tacca Olivier, PhD | Contact | +33 3 80 44 74 22 | o.tacca@fr.urgo.com |
| Name | Affiliation | Role |
|---|---|---|
| Senet Patricia, MD | Vascular dermatologist, APHP, Paris, France | Principal Investigator |
| Dissemond Joachim, MD | Clinic for dermatology, Essen- Germany | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D014647 | Varicose Ulcer |
| ID | Term |
|---|---|
| D014648 | Varicose Veins |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D007871 | Leg Ulcer |
Not provided
Not provided
| ID | Term |
|---|---|
| D058128 | Compression Bandages |
| ID | Term |
|---|---|
| D001458 | Bandages |
| D004864 | Equipment and Supplies |
Not provided
Not provided
Prospective, multi centre, non-comparative study
Not provided
Not provided
Not provided
Not provided
Oedema reduction from baseline (D0) and last assessment by measuring the limb circumference (in cm), using a tape:
| 6 weeks or last assessment |
| Patient quality of Life (EuroQoL 5D-5L) | EuroQoL 5D-5L between baseline and at last visit. The questionnaire essentially consists of a descriptive system including 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and a visual analogue scale (EQ VAS) from "the worst health you can imagine" (0) to "the best health you can imagine" (100). | 6 weeks or last assessment |
| Evolution of the periwound skin | Evolution of the peri-wound skin at each visit according to the following parameters:
| 6 weeks or last assessment |
| Safety analysis | Nature and number of adverse event related to the use of the testing compression system (serious/ non-serious) | 6 weeks or last assessment |
| D012883 |
| Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |